Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Antonio Palumbo; Asher Chanan‐Khan; Katja Weisel; Ajay K. Nooka; Tamás Masszi; Meral Beksaç; Ivan Špıčka; Vânia Hungria; María‐Victoria Mateos; Tomer M. Mark

doi:10.1200/jco.2016.34.15_suppl.lba4

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Identifier:nobleid.org/w1/20260515/D8773CF2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D8773CF2.svg?ark=w1%2F20260515%2FD8773CF2)](https://nobleid.org/work/w1/20260515/D8773CF2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

María‐Victoria Mateos

Tomer M. Mark

Claim authorship of this work

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Identifier:nobleid.org/w1/20260515/D8773CF2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D8773CF2.svg?ark=w1%2F20260515%2FD8773CF2)](https://nobleid.org/work/w1/20260515/D8773CF2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

María‐Victoria Mateos

Tomer M. Mark

Claim authorship of this work